Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer‐Associated Thrombosis: The Observational ROADMAP‐CAT Study

Konstantinos Syrigos (1) , Dimitra Grapsa (1) , Rabiatou Sangare (2, 3) , Ilias Evmorfiadis (3, 2) , Annette K Larsen (2, 3) , Patrick van Dreden , Paraskevi Boura (1) , Andriani Charpidou (1) , Elias Kotteas (1) , Theodoros N Sergentanis (4) , Ismail Elalamy (1, 3, 2) , Anna Falanga , Grigoris T Gerotziafas (1, 2, 3)

1 NKUA - National and Kapodistrian University of Athens
2 CRSA - Centre de Recherche Saint-Antoine
3 SU - Sorbonne Université
4 CHU Tenon [AP-HP]

BACKGROUND: The aim of this prospective study was to identify the most clinically relevant hypercoagulability biomarkers in lung adenocarcinoma patients for elaboration of an improved risk assessment model (RAM) for venous thromboembolism (VTE). SUBJECTS, MATERIALS, AND METHODS: One hundred fifty ambulatory patients with lung adenocarcinoma were prospectively enrolled. Thrombin generation, procoagulant phospholipid-dependent clotting time (Procoag-PPL), tissue factor activity (TFa), factor VIIa (FVIIa), factor V (FV), antithrombin, D-Dimers, P-selectin, and heparanase levels were assessed in platelet-poor plasma at inclusion (baseline) and at the end of the third chemotherapy cycle (third chemotherapy). Cox regression analysis was used to identify independent VTE predictors. RESULTS: At baseline, patients had significantly attenuated thrombin generation, shorter Procoag-PPL, higher levels of TFa, D-Dimers, and heparanase, and lower levels of FVIIa and P-selectin, compared with controls. A significant increase in Procoag-PPL, FV, and FVIIa and a decrease of P-selectin levels were observed between baseline and third chemotherapy. Hospitalization within the last 3 months prior to assessment, time since cancer diagnosis less than 6 months, mean rate index (MRI) of thrombin generation, and Procoag-PPL were independently associated with symptomatic VTE. Accordingly, a prediction model including Procoag-PPL and MRI showed significant discriminating capacity (area under the curve: 0.84). CONCLUSION: Ambulatory patients with lung adenocarcinoma may display pronounced blood hypercoagulability due to decreased Procoag-PPL, increased endothelial cell activation, and increased degradation of fibrin. Incorporation of Procoag-PPL and MRI of thrombin generation may improve the accuracy of a VTE-RAM in the above setting. IMPLICATIONS FOR PRACTICE:The prospective ROADMAP-CAT study identified two biomarkers of hypercoagulability, the procoagulant phospholipid-dependent clotting time (Procoag-PPL) and the mean rate index (MRI) of the propagation phase of thrombin generation assessed with the Calibrated Automated Thrombinoscope, as being clinically relevant for the classification of ambulatory patients with lung adenocarcinoma receiving a maximum of one cycle of chemotherapy into high and intermediate/low risk for venous thromboembolism. Measurement of Procoag-PPL and MRI within 1 month after the administration of the first chemotherapy cycle provides significant accuracy of the assessment. Association of the Procoag-PPL and MRI with the clinical risk assessment model for cancer-associated thrombosis in ambulatory patients with solid tumors (COMPASS-CAT RAM) further improved its accuracy.

Mots clés: Cancer-associated thrombosis; Thrombin generation; Venous thromboembolism; Lung cancer; Risk assessment model; Cancer‐associated thrombosis

Domaines: Cancer; Santé publique et épidémiologie

Konstantinos Syrigos, Dimitra Grapsa, Rabiatou Sangare, Ilias Evmorfiadis, Annette K Larsen, et al.. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer‐Associated Thrombosis: The Observational ROADMAP‐CAT Study. Oncologist, 2018, 23 (11), pp.1372-1381. ⟨10.1634/theoncologist.2017-0530⟩. ⟨hal-01989912⟩